Page 170 - Haematologica3

J. Koreth et al.
5. Pai CC, Hsiao HH, Sun K, et al.
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue spe- cific and is associated with interleukin-6 levels. Biol Blood Marrow Transplant. 2014;20(12):1899-1904.
6. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus- tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA. 2004; 101(21):8120-8125.
7. Kim JS, Lee JI, Shin JY, et al. Bortezomib can suppress activation of rapamycin-resis- tant memory T cells without affecting reg- ulatory T-cell viability in non-human pri- mates. Transplantation. 2009;88(12):1349- 1359.
8. Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome inhibi- tion by bortezomib on murine acute graft- versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointesti- nal toxicity. Blood. 2005;106(9):3293-3299.
9. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-ver- sus-host disease: comparative efficacy of bortezomib and PS-1145. Blood. 2006;107(2):827-834.
10. Liang Y, Ma S, Zhang Y, et al. IL-1beta and TLR4 signaling are involved in the aggra- vated murine acute graft-versus-host dis- ease caused by delayed bortezomib admin-
istration. J Immunol. 2014;192(3):1277-
1285.
11. Koreth J, Stevenson KE, Kim HT, et al.
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allo- geneic stem cell transplantation from HLA- mismatched unrelated donors. Blood. 2009; 114(18):3956-3959.
12. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versus-host dis- ease prophylaxis in HLA-mismatched unre- lated donor transplantation. J Clin Oncol. 2012;30(26):3202-3208.
13. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111(1):453-462.
14. Johnston L, Florek M, Armstrong R, et al. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(4):581-588.
15. Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD pro- phylaxis after matched, related donor allo- geneic HCT. Blood. 2014;124(8):1372-1377.
16. Gray R. A class of k-sample tests for com- paring the cumulative incidence of a com- peting risk. Annals of Statistics. 1988;16(3):1141-1154.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a compet- ing risk. J Am Stat Assoc. 1999;94:496-509.
18. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no dif- ference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22(14):2816-2825.
19. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplanta- tion from human leukocyte antigen-identi- cal siblings versus human leukocyte anti- gen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24(36):5695-5702.
20. Ringden O, Pavletic SZ, Anasetti C, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113(13):3110-3118.
21. Soiffer RJ, Kim HT, McGuirk J, et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chron- ic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). Blood. 2016;128(22):505.
530
haematologica | 2018; 103(3)